Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Agribody Technologies is an agricultural biotechnology company that specializes in enhancing crop yields and extending the shelf life of perishable food products. The company's core technology involves the co-suppression or down-regulation of the Deoxyhypusine synthase (DHS) gene, which regulates the activation of the Eukaryotic translation initiation factor 5A (eIF5A) protein, a key switch for plant senescence and stress response. By modulating these targets, Agribody develops crops with significantly higher tolerance to drought, salt, and heat, as well as increased biomass and delayed spoilage. Their technology is delivered through diverse methods including CRISPR gene editing, RNA interference, and traditional molecular breeding. In 2020, the company was acquired by Global Clean Energy Holdings to integrate its yield-enhancing technology into sustainable biofuel feedstocks like Camelina.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Agribody Technologies.